Abstract
Lecanemab (Leqembi (R)) is approved in the United States for the treatment of Alzheimer's disease (AD) to be initiated in early AD (mild cognitive imp......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
